Phospholine Iodide Drug Information

Reduction of Elevated IOP Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. Accommodative Esotropia Concomitant esotropias with a significant accommodative component.

Although the relationship, if any, of retinal detachment to the administration of echothiophate iodide for ophthalmic solution has not been established, retinal detachment has been reported in a few cases during the use of echothiophate iodide for ophthalmic solution in adult patients without a previous history of this disorder. Stinging, burning, lacrimation, lid muscle twitching, conjunctival and ciliary redness, browache, induced myopia with visual blurring may occur. Activation of latent iritis or uveitis may occur.

Iris cysts may form, and if treatment is continued, may enlarge and obscure vision. This occurrence is more frequent in children. The cysts usually shrink upon discontinuance of the medication or by reducing the frequency of instillation.

Rarely, they may rupture or break free into the aqueous. Regular examinations are advisable when the drug is being prescribed for the treatment of accommodative esotropia. Prolonged use may cause conjunctival thickening, obstruction of nasolacrimal canals.

Lens opacities have been reported with echothiophate iodide. Paradoxical increase in IOP may follow anticholinesterase instillation. This may be alleviated by prescribing a sympathomimetic mydriatic such as phenylephrine.

Cardiac irregularities.

Drug Interactions Echothiophate iodide for ophthalmic solution potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides. Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects of echothiophate iodide for ophthalmic solution.

Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with echothiophate iodide for ophthalmic solution. It is also not known whether echothiophate iodide for ophthalmic solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Echothiophate iodide for ophthalmic solution should be given to a pregnant woman only if clearly needed.

Pediatric Use Safety and effectiveness in pediatric patients have been established.

Active uveal inflammation. Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block. Hypersensitivity to the active or inactive ingredients.